MSTN and hepatocellular carcinoma: Over a 2.5-year median follow-up period (interquartile range [IQR], 1.2–4.5 years), the 5-year HCC incidence rates were 17.6% in the high myostatin group (n = 52) and 2.6% in the low myostatin group (n = 20) (hazard ratio [HR] 7.51, 95% CI 4.43–12.75, p < 0.001 by the log-rank test; Figure 1B).